1. Home
  2. Product Information
  3. Potassium-Competitive Acid Blocker

Product Information

Potassium-Competitive Acid Blocker

Compound Code RQ-00000004
Primary Target Indications GERD (RE/NERD)
Development Stage Phase1 (US/JPN)
Portfolio for global development, manufacturing, and marketing rights
Product Summary

The potassium-competitive acid blocker program targeting gastro-esophageal reflux disease (GERD) is in clinical development for the first development compound, RQ-4. Phase 1 studies were completed in US, Korea and Japan, a Phase 3 study for GERD is ongoing in Korea. A potassium-competitive acid blocker has a different mechanism for controlling the secretion of stomach acids in the treatment of GERD from the current drug of choice, the proton pump inhibitor (PPI). Compared to PPIs, in animal models RQ-4 has been shown to be faster in controlling the secretion of gastric acids and to have a sustained effect. In the Phase 1 clinical test conducted in the U.S., RQ-4's safety, tolerability and pharmacokinetics were confirmed. Also, pharmacological properties, including its rapid and potent inhibition of gastric acid secretion from the first dose, its effectiveness independent of acid secretion stimulated by meals, and its inhibition of acid secretion at night when administered before sleeping, were confirmed using biomarkers.

In addition, the clinical trials currently implemented by licensee have been in good progress. This compound falls under the category of acid reducer, which has a global market size of approximately 2,500 billion yen. It is thus expected to have a large market share, maintaining competitive advantages over PPI or H2 blockers.

Licensing Status

Page Top

Corporate Information
CEO Message
Company Overview
Vision, Management Principle and Culture
Quality Policy
Corporate Governance
Business Model
Origins of Our Corporate Name and Logo
Access
Press Release
Research & Development
Collaboration
Partnering in Research
What are Research Tools?
Research Tool Licensing
Product Information
Anidulafungin
Ziprasidone
Dalbavancin
Potassium-Competitive Acid Blocker
5-HT4 Partial Agonist
5-HT2B Antagonist
Motilin Receptor Agonist
Licensing Status
Shareholder and Investor Information
Vision, Management Principle and Culture
Corporate Governance
Outline of Securities Matters
IR Library
IR Calendar
Disclaimer
IR Related News
Understanding RaQualia Pharma! RaQualia FAQ
RaQualia's History
What does RaQualia Pharma do?
How Does RaQualia Earn Revenues?
What About Dividends?
What are RaQualia's strengths?
What Does the Future Hold for RaQualia Pharma?
Contributions to Society
Corporate Contributions
Contributions to the Community
Press Release
Topics